All In Biotech

Drug Trial Radar · NCT06496568

A Study Evaluating Single-agent Inavolisib, Inavolisib Plus Atezolizumab in PIK3CA-Mutated Cancers

A Phase I/Ib Study Evaluating Single-Agent Inavolisib, Inavolisib Plus Atezolizumab in PIK3CA-Mutated Cancers

Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

30

Planned (sponsor's estimate)

Start

Dec 11, 2023

Primary completion

Jul 21, 2027

Study completion Jul 21, 2027

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Jul 11, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to assess the safety and efficacy of inavolisib as a single-agent and in combination with atezolizumab in participants with phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform (PIK3CA)-mutated cancers, including previously treated head and neck squamous cell carcinoma (HNSCC).

Conditions

  • PIK3CA-Mutated Cancers

Interventions

  • InavolisibDrug

    Participants will receive inavolisib, 9 milligram (mg), PO, QD on Days 1-21 of each 21-day cycle.

  • AtezolizumabDrug

    Participants will receive atezolizumab, 1200 mg, as IV infusion Q3W on Day 1 of each 21-day cycle.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants with Select Treatment-related Toxicities (TRT) in Arm BTime frame: Day 1 of Cycle 1 to Day 3 of Cycle 2 (each cycle = 21 days)
  2. Percentage of Participants with Adverse Events (AEs) and serious adverse events (SAEs)Time frame: From baseline up to approximately 3 years

Locations

5 sites in 3 countries. Site status is shown where the registry gives one.

  • Vanderbilt-Ingram Cancer Ctr

    Nashville, Tennessee

  • BC Cancer Vancouver Centre

    Vancouver, British Columbia, Canada

  • Princess Margaret Cancer Center

    Toronto, Ontario, Canada

  • Jewish General Hospital

    Montreal, Quebec, Canada

  • Samsung Medical Center

    Seoul, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.